Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.

Leukemia · 2026 · PMC13149028 · PMID 41803402

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.3000

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

DP-NP-HVG mismatches showed a trend towards a possible protective effect (HR 0.4, 95% CI 0.2–1.1, p = 0.07), while DP-NP-GVH mismatches conferred no significant benefit (HR 1.03, 95% CI 0.5-2.0, p = 0.9).

also in 53,322 other papers

a favorable trendp = 0.07so close (0.05 < p ≤ 0.1)

Similarly, PFS was highest in DP-P pairs (52%) compared with others (39%), suggesting a favorable trend that did not reach statistical significance (HR 0.7, 95% CI 0.5–1.03, p = 0.07) (Fig. 3A ).

also in 1,335 other papers

did not reach statistical significancep = 0.3not close (p > 0.1)

Two-year OS was higher with DP-P and DP-NP-HVG pairs (54% and 52%, respectively) compared DP-M pairs (43%), though these differences did not reach statistical significance (DP-P vs DP-M: HR 0.8, 95% CI 0.5–1.2, p = 0.3; DP-MM-HVG vs DP-M: HR 0.7, 95% CI 0.3–1.5, p = 0.3) (Fig. 2A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.